NCT07203287PHASE4RecruitingAccepts Healthy Volunteers

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

The University of Texas Medical Branch, Galveston

Start Date

8/26/2025

Completion Date

8/26/2027

Summary

The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."

Detailed Description

Participants will be randomized into one of the two groups (Group 1-Given rocuronium and sugammadex as part of one of the standard regimens of neuromuscular blockade and reversal or Group 2-Given cisatracurium and neostigmine as part of one of the standard regimens of neuromuscular blockade and reversal). Both of which are current standard of care practices. Appropriate reversal will be performed and documented, and the patient will go to the recovery room or intensive care unit as planned preoperatively. The patients will be assessed postoperatively for up to 7 days for any signs of respiratory complications, including but not limited to: 1. Atelectesis 2. Hypoxia 3. Respiratory distress/failure 4. Pneumonia 5. Pneumothrax

Eligibility Criteria

Age Range: 18 years to 80 years

Inclusion Criteria: * The subject is able and willing to provide and sign informed consent * The subject must be between 18 and 80 years of age * The subject should have chronic kidney disease as defined by glomerular filtration rate * The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade Exclusion Criteria: * Any patient under the age of 18 * Any patient over the age of 80 * Any patient with end stage renal disease * Any patient requiring dialysis * Patients presenting for Renal Transplantation * Pregnant Female * Any patient in the correctional system * Urgent or Emergent procedure * The surgery requires intubation post-operatively * Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine

Interventions

DRUG

Rocuronium

DRUG

Cisatracurium

DRUG

Sugammadex

DRUG

Neostigmine

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Post Operative Pulmonary ComplicationsNeuromuscular BlockadeGeneral Anesthesia

Locations

University of Texas Medical Branch

Galveston, Texas 77554

United States